Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Innodata Inc (INOD) vs Merck & Co., Inc. (MRK) Price & Performance

Innodata IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Innodata Inc vs Merck & Co., Inc. — how do they compare? Innodata Inc trades at $62.62 (market cap $2.05B), while Merck & Co., Inc. trades at $132.78 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 157× Innodata Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Innodata Inc pays none. Which is the better fit depends on your goals.

INODMRK
Market Cap
$2.05B$321.77B
Sector
TechnologyHealth
52-Week High
$121.50$131.84
52-Week Low
$34.45$77.60
Enterprise Value
$1.80B$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Innodata Inc

INOD trades at $61.40, down 1.33% today, but maintains a bullish technical signal with oscillators supporting upside momentum. The company reported strong Q2 2026 results, beating EPS estimates with $0.41 versus $0.21 expected, driven by 58% revenue growth and AI-driven demand expansion. Valuation ratios remain elevated with a P/E of 48.62, reflecting high growth expectations.

Outlook is positive given consistent earnings beats and AI sector tailwinds, but risks include premium valuation sensitivity and customer concentration. Analyst consensus is bullish with a $130 price target, suggesting significant upside potential if execution continues.

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Innodata Inc

Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.

Read more on INOD

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK